Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER3 | P43115 | 5/20 | 0.68 |
| ▸ | PTGER4 | P35408 | 5/20 | 0.68 |
| ▸ | PTGER2 | P43116 | 5/20 | 0.68 |
| ▸ | PTGER1 | P34995 | 4/20 | 0.68 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.63 |
| ▸ | PKM | P14618 | 1/20 | 0.63 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.62 |
| ▸ | PLA2G2D | Q9UNK4 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.52 |
| ▸ | GSK3B | P49841 | 1/20 | 0.51 |
| ▸ | BACE1 | P56817 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7191225 | 1.00 | PTGER3 (0.68) | PTGER3PTGER4PTGER2PTGER1HDAC8 | |
| SCHEMBL6035013 | 0.91 | HDAC8 (0.80) | PTGER3PTGER4PTGER2PTGER1HDAC8 | |
| SCHEMBL18538447 | 0.91 | HDAC8 (0.65) | PTGER3PTGER4PTGER2PTGER1HDAC8 | |
| SCHEMBL6035015 | 0.91 | HDAC8 (0.80) | PTGER3PTGER4PTGER2PTGER1HDAC8 | |
| SCHEMBL5119409 | 0.90 | HDAC8 (0.61) | PTGER3PTGER4PTGER2PTGER1HDAC8 | |
| SCHEMBL3218760 | 0.90 | HDAC8 (0.65) | PTGER3PTGER4PTGER2PTGER1HDAC8 | |
| SCHEMBL5119417 | 0.90 | HDAC8 (0.61) | PTGER3PTGER4PTGER2PTGER1HDAC8 | |
| SCHEMBL3218772 | 0.90 | HDAC8 (0.65) | PTGER3PTGER4PTGER2PTGER1HDAC8 | |
| SCHEMBL3208404 | 0.89 | HDAC8 (0.64) | PTGER3PTGER4PTGER2PTGER1HDAC8 | |
| SCHEMBL3208391 | 0.89 | HDAC8 (0.64) | PTGER3PTGER4PTGER2PTGER1HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0728128-B1 | SUBSTITUTED PHENYL COMPOUNDS | RHONE POULENC RORER LTD (GB) | 1998-09-16 | — | — | EP | claimed |
| EP-0728128-A1 | SUBSTITUTED PHENYL COMPOUNDS | RHONE-POULENC RORER LIMITED (GB) | 1996-08-28 | — | — | EP | claimed |
| WO-1995013262-A1 | SUBSTITUTED PHENYL COMPOUNDS | RHONE-POULENC RORER LIMITED (GB) | 1995-05-18 | — | — | WO | claimed |
| EP-2595952-B1 | AGONISTS OF GPR40 | CONNEXIOS LIFE SCIENCES PVT LTD (IN) | 2020-11-18 | — | — | EP | disclosed |
| US-9278915-B2 | Agonists of GPR40 | CONNEXIOS LIFE SCIENCES PVT LTD (IN) | 2016-03-08 | — | — | US | disclosed |
| US-20130237571-A1 | AGONISTS OF GPR40 | Conexios Life Sciences PVT. LTD. (IN) | 2013-09-12 | — | — | US | disclosed |
| EP-2595952-A1 | AGONISTS OF GPR40 | Connexios Life Sciences Pvt. Ltd. (IN) | 2013-05-29 | — | — | EP | disclosed |
| WO-2012011125-A1 | AGONISTS OF GPR40 | CONNEXIOS LIFE SCIENCES PVT. LTD. (IN) | 2012-01-26 | — | — | WO | disclosed |
| US-6211234-B1 | BENZONITRILE COMPOUNDS WITH ETHER AND SULFIDE GROUPS WITH CARBOXY ACID | RHONE-POULENC RORER LIMITED (GB) | 2001-04-03 | — | — | US | disclosed |
| EP-0728128-B1 | SUBSTITUTED PHENYL COMPOUNDS | RHONE POULENC RORER LTD (GB) | 1998-09-16 | — | — | EP | disclosed |
| EP-0728128-A1 | SUBSTITUTED PHENYL COMPOUNDS | RHONE-POULENC RORER LIMITED (GB) | 1996-08-28 | — | — | EP | disclosed |
| WO-1995013262-A1 | SUBSTITUTED PHENYL COMPOUNDS | RHONE-POULENC RORER LIMITED (GB) | 1995-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130237571-A1 | AGONISTS OF GPR40 | GPR65, GPR55, GPR68 | PTGER3 433/4885PTGER4 257/4885PTGER2 421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.